PatientsVille.com Logo

Post-traumatic and Abilify

PatientsVille

Post-traumatic Symptoms and Causes

Post-traumatic stress disorder (PTSD) is a real illness. You can get PTSD after living through or seeing a traumatic event, such as war, a hurricane, sexual assault, physical abuse, or a bad accident. PTSD makes you feel stressed and afraid after the danger is over. It affects your life and the people around you.

PTSD can cause problems like

  • Flashbacks, or feeling like the event is happening again
  • Trouble sleeping or nightmares
  • Feeling alone
  • Angry outbursts
  • Feeling worried, guilty, or sad

PTSD starts at different times for different people. Signs of PTSD may start soon after a frightening event and then continue. Other people develop new or more severe signs months or even years later. PTSD can happen to anyone, even children.

Treatment may include talk therapy, medicines, or both. Treatment might take 6 to 12 weeks. For some people, it takes longer.

NIH: National Institute of Mental Health

Check out the latest treatments for post-traumatic

post-traumatic treatment research studies

Abilify clinical trials, surveys and public health registries


Find Drug Side Effect reports



Abilify Side Effects

Weight Increased (748)
Tremor (534)
Tardive Dyskinesia (518)
Insomnia (479)
Pregnancy (435)
Dyskinesia (391)
Dizziness (324)
Somnolence (317)
Nausea (313)
Restlessness (303)
Headache (293)
Psychotic Disorder (287)
Fatigue (287)
Akathisia (286)
Anxiety (277)
Agitation (256)
Vomiting (254)
Convulsion (243)
Delusion (233)
Blood Glucose Increased (228)
Depression (192)
Dystonia (189)
Feeling Abnormal (188)
Vision Blurred (185)
Suicidal Ideation (179)
Death (178)
Mania (178)
Hallucination (176)
Aggression (174)
Neuroleptic Malignant Syndrome (169)
Fall (169)
Confusional State (167)
Weight Decreased (150)
Extrapyramidal Disorder (140)
Dyspnoea (136)
Hallucination, Auditory (136)
Schizophrenia (135)
Gait Disturbance (135)
Abnormal Behaviour (135)
Muscle Spasms (133)
Suicide Attempt (131)
Loss Of Consciousness (128)
Hyperhidrosis (125)
Musculoskeletal Stiffness (123)
Dysphagia (123)
Asthenia (121)
Blood Creatine Phosphokinase Increased (110)
Oedema Peripheral (109)
Completed Suicide (108)
Irritability (105)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

dystonia...on the right hand

Abilify for BiPolar Disorder, how does it work for you?

Abilify lifts the cloud of depression for me But - the sweating is profuse -- just dripping if I do any kind of movement

Abilify, lost everything, could'nt stop gambling until I got off of it.

Abilify, side effects ruined my life. I have compulsive bahavior, I gambled I lost everything. I am looking for a good Lawyer. (409) 548-0460.

As human experience is limited, administration of aripiprazole should be used in pregnancy only if the potential benefit to the mother outweighs the potential risk to the foetus.

Can it cause constipation? My lil was had been bad

Can't sleep any more than 3 to 4 hours at a time anyone else with that problem?

Developed bruxism after starting abilify and lithium

Did not know what was going on, panic attacks yesterday. muscle cramping and tremor, sleeplessness, its all here, going off of this. very scary

Look plain and simple this drug is no joke, I don't work for anybody in relation to this post.. I'm just your normal everyday person with crap salary. Ive been taking Propecia since I was 22 I didn't start having problems until I

14 month old girl developed erythematous skin lasion on left cheek 5 days post prevnar vaccine. 24 hrs later lesion weeping straw colored fluid and crusted. seen at pediatrician 7 days post prevnar vaccine and also diagnosed with ear infection. Start

20mg is a lot. I've heard that some doctors ramp you up to 20 when it is totally unnecessary. I can identify with the sleepiness and I was only on 10. Read my post below about switching to 5, but don't do it without talking to you

4 months post dysport injection and still unable to speak correctly. Drooping on one side of face, eyes still not normal, hard to recognize myself as my eyes were big and now they look to be about half the size. Entire face looks flattened. When w

48YO male, obese, diabetic, hypertensive, mild anxiety and depression. R BKA, R Acetabula fracture 13 years ago from motorcycle accident. Swollen gall bladder removed during hospitalization. Current meds include Metformin (withheld pre- and post- ct)

54y/o, WM, Status post quadruple coronary artery bypass graft surgery(10 months ago). Surgery went well, only complication was a pretty large left pleural effusion requiring chest tube placement. Resolved well, no further problems

62 year old male. Velcade was a great treatment for my Multiple Myaloma, however the post treatment side effects have been bothersum and painful. My feet feel like they have pins stuck in them. In the last month it has spread from my toes to the bott

A 40-year-old manager, at a prominent legal firm in L.A., experiences abdominal pain post lunch. He goes to the restroom a couple of times, but continues to experience pain and cramps. He eventually decides to get himself examined. While questioning

After 1st dose, headache, aches, fatigue, severe vomiting and general unwell feeling for 3 weeks post. After 2nd injection same indications but not as intense, although severe fatigue. I am concerned about my next injection in 4 months!

Also one other thing. Please post which Mucinex you tried. There is regular Mucinex, Mucinex-D or Mucinex DM. The DM is for the<a href='http://www.google.com/search?hl=en&amp;client=safari&amp;rls=en&amp;

Post-traumatic Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Aripiprazole 6-week group;   Drug: Aripiprazole 8-week group
Outcome Measures: Quality of Life Scale (QOLS);   Montgomery-Åsberg Depression Rating Scale
2 Unknown  Aripiprazole and Topiramate on Free-Choice Alcohol Use
Condition: Alcohol Dependence
Interventions: Drug: Double Placebo;   Drug: Aripiprazole 15, placebo;   Drug: Aripiprazole 7.5, Placebo;   Drug: Topiramate 100, Placebo;   Drug: Topiramate 200, Placebo;   Drug: Topiramate 100, Aripiprazole 15;   Drug: Topiramate 100, Aripiprazole 7.5;   Drug: Topiramate 100, Aripiprazole 15mg;   Drug: Topiramate 200, Aripiprazole 7.5mg;   Drug: Topiramate 200, Aripiprazole 15
Outcome Measures: Number of alcoholic drinks consumed in a laboratory setting;   Safety and tolerability of the medications singly and in combination, compared to placebo;   Drinks consumed during the medication titration period
3 Recruiting Double-Blind Placebo Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia
Condition: Hyperprolactinemia
Interventions: Drug: Aripiprazole;   Drug: Placebo
Outcome Measures: To determine if adjunct aripiprazole will resolve or improve prolactin related hormonal side effects (amenorrhea, oligomenorrhea, galactorrhea).;   To test whether adjunctive aripiprazole will improve quality/perceived quality of life.;   To identify if adjunct aripiprazole will improve bone turnover as measured by assays of osteoblastic and osteoclastic activity.;   To examine side effects associated with adjunctive aripiprazole versus placebo and conduct a cost analysis of adjunctive aripiprazole use.;   To evaluate the mediator effects of estrogen, progesterone, prolactin effects on quality of life, bone turnover and sexual functioning.
4 Unknown  The New Strategy for Pharmacological Treatment in People With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Rispridoen and Aripiprazole;   Drug: Risperidne;   Drug: Abilify
Outcome Measures: SANS(Scale for the Assessment of Negative Symptoms);   SARS(Simpson-Angus Rating Scale);   Drug Attitude Inventory;   Side effect checklist
5 Recruiting Study to Evaluate the Efficacy and Safety of Aripiprazole
Condition: Autism
Intervention: Drug: Aripiprazole
Outcome Measures: irritability subscale of the aberrant behavior checklist;   Change from baseline in ABC-subscale of lethargy/social withdrawal, stereotypic behavior, hyperactivity, inappropriate speech;   Change of CGI-S, CGI-I from baseline;   Change of Behavioral problems from baseline;   Change of Adaptive Skills from baseline;   Change of Parental stress from baseline
6 Recruiting Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients
Condition: Bipolar I Disorder
Interventions: Drug: Intramuscular (IM) Depot Aripiprazole;   Drug: Intramuscular (IM) Depot Placebo
Outcome Measures: Time from randomization to recurrence of any mood episode during Double-Bind Placebo Controlled phase;   Proportion of subjects meeting criteria for recurrence of any mood episode(manic, mixed, depressive);   Mean change from randomization to endpoint in the CGI-BP-S (mania) score;   Time from randomization to recurrence defined by hospitalization for a mood episode.
7 Unknown  Neuroimaging Of Treatment Effects in Treatment-Resistant Depression
Condition: Major Depressive Disorder
Intervention: Drug: escitalopram and adjunctive aripiprazole and placebo
Outcome Measures: Use of PET and fMRI to demonstrate the differential pattern of dopaminergic activity, dopamine receptor binding in the putamen and caudate and correlation these findings to MADRS in MDD subjects treated with escitalopram and aripiprazole.;   Correlation of D2binding before and after adjunctive aripiprazole with emergence of extrapyramidal symptoms and akathisia.
8 Recruiting Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Aripiprazole and aripiprazole once-monthly;   Drug: Paliperidone and paliperidone palmitate
Outcome Measures: Mean change from Baseline in quality of life;   Investigator's assessment of overall effectiveness;   Mean change from Baseline in clinical global impression;   Mean change from Baseline in quality of life using QLS;   Mean change from Baseline in subjective well-being using SWN-S;   Mean change from Baseline in tolerability and quality of life using TooL;   Safety and tolerability;   Risk of suicidality
9 Recruiting Aripiprazole and Prolactin Study
Condition: Hyperprolactinemia
Intervention: Drug: Aripiprazole
Outcome Measures: Normalization or reduction in prolactin sufficient to restore gonadal function;   Normalization or improvement in bone mineral density
10 Recruiting A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Adverse events;   Positive and Negative Syndrome Scale (PANSS);   Clinical golobal impression (CGI);   Children's Global Assessment Scale (CGAS)
11 Unknown  Aripiprazole Augmentation Therapy in Treatment-resistant Depression
Condition: Therapy-resistant Depression
Intervention: Drug: Aripiprazole
Outcome Measure: rate of response as defined by a more or equal 50 % reduction of baseline HAM-D (Hamilton Depression Rating scale)
12 Recruiting Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia
Condition: Schizophrenia
Intervention: Drug: Aripiprazole
Outcome Measures: Prolactin level;   PANSS (positive and negative syndrome scale) score
13 Recruiting A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
Condition: Schizophrenia
Interventions: Drug: Aripiprazole Low (2 mg/day);   Drug: Aripiprazole Mid (6 - 12 mg/day);   Drug: Aripiprazole High (24 - 30 mg/day)
Outcome Measures: Positive and Negative Syndrome Scale (PANSS) total sore;   PANSS score;   Clinical Global Impression (CGI);   Children's Global Assessment Scale (CGAS);   Adverse events;   Electrocardiogram
14 Unknown  Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole
Conditions: Schizophrenia;   Sensory Gating
Intervention: Drug: Aripiprzole
Outcome Measure: MEG/EEG and MRI data will be compared with the results of a neuropsych battery and symptom rating scales prior to initiation with aripiprazole and after subject has been on a stable dose of aripiprazole for three month.
15 Unknown  Aripiprazole and Resistant Postpartum Depression
Condition: Postpartum Depression
Intervention: Drug: aripiprazole
Outcome Measures: Montgomery Asberg Depression Rating Scale;   Udvalg for Kliniske Undersogelser Scale
16 Recruiting Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder
Condition: Bipolar I
Intervention: Drug: Aripiprazole
Outcome Measures: Number and percentage of subjects with adverse events;   Injection Site Pain measured by the Visual Analog Scale (VAS);   Number and percentage of subjects with clinically significant abnormal laboratory test results, vitals, ECGs;   Extrapyramidal Symptoms (EPS) will be assessed by change from baseline on Abnormal Involuntary Movement Scale (AIMS), Simpson-Angus Scale (SAS), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS used in Japan), and Barnes Akathisia Rating Scale (BARS);   Percentage of subjects who remain stable at endpoint
17 Unknown  Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Placebo;   Drug: D-cycloserine;   Other: fMRI
Outcome Measures: Aberrant Behavior Checklist (ABC) Irritability Subscale;   Clinical Global Impression (CGI) Scale;   ABC Subscales;   Vineland Maladaptive Behavior Subscales;   A modified version of the Compulsion Subscale of the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS);   Autism Diagnostic Observation Schedule (ADOS);   Social Reciprocity Scale (SRS)
18 Recruiting Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART)
Condition: Autistic Disorder
Interventions: Drug: Aripiprazole;   Drug: Risperidone
Outcome Measure: To identify phenotypic and genetic traits that predict response to aripiprazole and risperidone in Autistic Disorder
19 Recruiting Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind Placebo-Controlled Pilot Study
Conditions: Bipolar Disorder;   Depressive Episode
Interventions: Drug: Low dose Adjunctive Aripiprazole;   Drug: placebo
Outcome Measure: Response rate
20 Recruiting A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence
Conditions: Schizophrenia;   Cocaine Dependence
Interventions: Drug: Aripiprazole;   Drug: Perphenazine
Outcome Measures: The proportion of negative urine drug screen results will be significantly greater in the subjects treated with aripiprazole than in those treated with perphenazine.;   The mean total self-report cocaine use days will be significantly fewer in subjects treated with aripiprazole than in those treated with perphenazine.;   The mean cocaine craving scores will be lower in subjects treated with aripiprazole than in those treated with perphenazine.